Tyler Van Buren
Stock Analyst at TD Cowen
(2.06)
# 2,685
Out of 4,814 analysts
57
Total ratings
39.13%
Success rate
-6.76%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $20.60 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $14.06 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $20.35 | +268.55% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $12.13 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $9.20 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $24.73 | +142.67% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $2.23 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $10.40 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $563.16 | +113.08% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $16.96 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $16.32 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $104.53 | -18.68% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $37.76 | -20.55% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.65 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.65 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $61.99 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $33.05 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.20 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $14.92 | +101.07% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.24 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.12 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $28.54 | +145.27% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.30 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.60 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.92 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.79 | +2,693.30% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $4.69 | +18,556.72% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $0.92 | +4,227.13% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $9.32 | +329.18% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $8.62 | +248.03% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.37 | +15,929.92% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.46 | +3,324.66% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.84 | +3,451.56% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.91 | +6,784.68% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.83 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.64 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $20.60
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $14.06
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $20.35
Upside: +268.55%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $12.13
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $9.20
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $24.73
Upside: +142.67%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $2.23
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $10.40
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $563.16
Upside: +113.08%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $16.96
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $16.32
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $104.53
Upside: -18.68%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $37.76
Upside: -20.55%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.65
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.65
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $61.99
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $33.05
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.20
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $14.92
Upside: +101.07%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $34.24
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.12
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $28.54
Upside: +145.27%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.30
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.60
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.92
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.79
Upside: +2,693.30%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $4.69
Upside: +18,556.72%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $0.92
Upside: +4,227.13%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $9.32
Upside: +329.18%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $8.62
Upside: +248.03%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.37
Upside: +15,929.92%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.46
Upside: +3,324.66%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.84
Upside: +3,451.56%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.91
Upside: +6,784.68%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $6.83
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $13.64
Upside: -